A phase 1/2, open-label, repeat-dose, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of MEDI-524, a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), in children at risk for serious RSV disease

Trial Profile

A phase 1/2, open-label, repeat-dose, dose-escalation study to evaluate the safety, tolerability, immunogenicity, and pharmacokinetics of MEDI-524, a humanized enhanced potency monoclonal antibody against respiratory syncytial virus (RSV), in children at risk for serious RSV disease

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Nov 2007

At a glance

  • Drugs Motavizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Therapeutic Use
  • Sponsors MedImmune
  • Most Recent Events

    • 19 Nov 2007 Status changed from in progress to completed.
    • 14 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top